{"id":"bcd-131-pegdarbepoetin-beta","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL320633","moleculeType":"Small molecule","molecularWeight":"484.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a pegylated darbepoetin beta analog, BCD-131 mimics endogenous erythropoietin by binding to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to shorter-acting erythropoiesis-stimulating agents. This mechanism is used to treat anemia associated with chronic kidney disease and chemotherapy.","oneSentence":"BCD-131 is a pegylated erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor to stimulate red blood cell production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:11.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Chemotherapy-induced anemia"}]},"trialDetails":[{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BCD-131 (pegdarbepoetin beta)","genericName":"BCD-131 (pegdarbepoetin beta)","companyName":"Biocad","companyId":"biocad","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCD-131 is a pegylated erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}